CN1062133C - Medicine for treating hypertensional sickness - Google Patents
Medicine for treating hypertensional sickness Download PDFInfo
- Publication number
- CN1062133C CN1062133C CN97108495A CN97108495A CN1062133C CN 1062133 C CN1062133 C CN 1062133C CN 97108495 A CN97108495 A CN 97108495A CN 97108495 A CN97108495 A CN 97108495A CN 1062133 C CN1062133 C CN 1062133C
- Authority
- CN
- China
- Prior art keywords
- hypertension
- medicine
- present
- tablet
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention discloses novel medicine for treating hypertension, which is characterized in that a sleep benefiting agent, reserpine, promethazine hydrochloride, a gastropin tablet, bendazol, hydrochlorothiazide, dihydralazine sulphate and chloroquine diphosphate are used as raw materials and then are prepared into a powder agent or a tablet proportionally. The medicine of the present invention is suitable for early-metaphase hypertension, and is also especially suitable for late-phase hypertension; thereby, the present invention has obvious treating effect to middle hypertension and heavy hypertension, and is suitable for hypertension patients who have combination canker.
Description
The present invention relates to a kind of medicine for the treatment of hypertension.
Hypertension is the common frdquently encountered disease of serious harm human health.The at present medicine such as the FUFANG JIANGYA PIAN of treatment hypertension, to early and middle portion hypertension good effect, but to late period the hypertension curative effect not obvious.And the patients with hypertension that is not suitable for merging Peptic Ulcers uses.
The purpose of this invention is to provide a kind ofly, and be suitable for merging the medicine of the treatment hypertension that the patients with hypertension of Peptic Ulcers uses not only to early stage, mid-term, late period hypertension good effect.
Medicine of the present invention is made (consumption is weight percentage) by following component:
Chlordiazepoxide 0.67%
Reserpine 0.02%
Promethazine hydrochloride 1.40%
Gastropin tablet 84.25%
Bendazol 1.01%
Hydrochlorothiazide 2.11%
Dihydralazine Sulphate 2.11%
Arechin (Polfa) 8.43%
Characteristics of the present invention, be suitable for anxiety, emotion agitation, hypotensive effect strong, can directly expand small artery, sympathetic nerve function is weakened, strengthen hypnosis and analgesic activity.In and gastric acid, cover and have mechanicalness protection effect on the ulcer surface, bendazol and Hydrochlorothiazide have collaborative blood pressure lowering, remove the smooth muscle spasm effect.Dihydralazine Sulphate (dihydralazine) and other depressor share and are applicable to late period or malignant hypertension, and its side effect is resisted by Arechin (Polfa), so pharmaceutical formulation of the present invention is reasonable.
Clinical use result represents, medicine of the present invention except that be suitable for early, the mid-term hypertension, particularly suitable hypertension in late period, centering, heavy hypertension curative effect obviously are better than FUFANG JIANGYA PIAN.And the present invention is faster than FUFANG JIANGYA PIAN action time, longer duration, blood pressure are more stable.Be applicable to the hyperpietic who merges Peptic Ulcers.Can correct hypertensive hemodynamic disturbance, there is stronger selectivity in the vascular smooth muscle road; Lasting to the effect of blood vessel dilating smooth muscle.Make decreased heart rate, blood pressure drops, blood pressure stabilization, evident in efficacy have no side effect low price.
In order to show the therapeutic effect of medicine of the present invention to the hypertensive patient, the present invention is through with one group of 200 routine patients with hypertension, high pressure (systolic pressure) is the above person of 20kpa (the above person of 150mmHg), and low pressure (diastolic pressure) is the above person of 13kpa (the above person of 100mmHg).Take medicine of the present invention, observed 6 months, 40 days is a course of treatment, totally four courses of treatment.
Instructions of taking: 0.3g/ time, day clothes 3 times.
Two groups: 200 routine hyperpietics, high pressure is (the following person of 150mmHg) below 20kPa, and low pressure is taken medicine of the present invention the above person of 12kPa (90mmHg), observes 6 months, and 40 days is a course of treatment, totally four courses of treatment.
Instructions of taking: 0.15g/ time, day clothes 3 times.
Test statistics shows: with medicine of the present invention one group of 200 routine hyperpietic done therapeutic test, obey medicine of the present invention after 7-10 days blood pressures tend to be steady.High pressure drops to 16-17.5kPa (120-130mmHg), and low pressure drop serve on four courses of treatment to 12kPa (90-93mmHg), and blood pressure is steadily normal.Total effective rate 98%.Obvious effective rate 86%.
With medicine of the present invention two group of 200 routine hyperpietic done therapeutic test, obey medicine of the present invention after 7-10 days blood pressures be tending towards positive ordinary index.Take total effective rate 98% after four courses of treatment, obvious effective rate 89%.
Embodiment
Take by weighing raw material by following proportioning:
Chlordiazepoxide chlordiazepoxide 120mg (10mg/ sheet * 12 slice)
Reserpine Reserpine 3.75mg (0.25mg/ sheet * 15 slice)
Promethazine hydrochloride (phenergan) promethalzini Hydrochloridum 250mg (25mg/ sheet * 10 slice)
Gastropin tablet Tabluts Aluminium Hydroxide compositae 15000mg (0.5g/ sheet * 30 slice)
Bendazol Dibazol 180mg (10mg/ sheet * 18 slice)
Hydrochlorothiazide Dihydrochlorothiazidum 375mg (25mg/ sheet * 15 slice)
Dihydralazine Sulphate (dihydralazine) Dihydral lazinie sulphate375mg (25mg/ sheet * 15 slice)
Arechin (Polfa) chloroquini phosphas 1500mg (0.25g/ sheet * 6 slice)
Production method is produced according to a conventional method.Above-mentioned raw material (finished medicines) is mixed porphyrize to be become powder or makes tablet.Also above-mentioned raw material (raw material of finished medicines) can be produced powder or tablet according to a conventional method.
Claims (3)
1. medicine for the treatment of hypertension is characterized in that it is the medicament of being made by the following weight proportion raw material:
Chlordiazepoxide 0.67%
Reserpine 0.02%
Promethazine hydrochloride 1.40%
Gastropin tablet 84.25%
Bendazol 1.01%
Hydrochlorothiazide 2.11%
Dihydralazine Sulphate 2.11%
Arechin (Polfa) 8.43%.
2. the medicine of treatment hypertension according to claim 1 is characterized in that said medicament is a said dosage form on any pharmaceutics.
3. the medicine of treatment hypertension according to claim 2 is characterized in that said medicament is powder or tablet.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN97108495A CN1062133C (en) | 1997-05-23 | 1997-05-23 | Medicine for treating hypertensional sickness |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN97108495A CN1062133C (en) | 1997-05-23 | 1997-05-23 | Medicine for treating hypertensional sickness |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1200269A CN1200269A (en) | 1998-12-02 |
| CN1062133C true CN1062133C (en) | 2001-02-21 |
Family
ID=5170471
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN97108495A Expired - Fee Related CN1062133C (en) | 1997-05-23 | 1997-05-23 | Medicine for treating hypertensional sickness |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1062133C (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1234578A3 (en) * | 2001-02-26 | 2003-01-08 | Lymphotec Inc. | Antitumor and antiviral medications and method for producing the same |
| CN1729982B (en) * | 2005-08-05 | 2010-05-05 | 福州辰星药业有限公司 | Prescription of compound bendazol and hydrochlorothiazide capsule and its preparation process |
| CN100498331C (en) * | 2006-08-15 | 2009-06-10 | 饶高雄 | Efficient liquid-phase chromatography method for determing reserpine content in rauvolfia plants |
-
1997
- 1997-05-23 CN CN97108495A patent/CN1062133C/en not_active Expired - Fee Related
Non-Patent Citations (4)
| Title |
|---|
| 《中国农村医学》(5) 1989.5.31 傅善杰，长期服用复方降压片治疗原发性高血压30例分析 * |
| 《中西医结合杂志》9(7) 1989.7.31 何世银等，威乐降压片治疗高血压病84例疗效观察 * |
| 《青海医药》2 1984.2.29 李大猷，复方降压胶囊的药物配伍分析 * |
| 《青海医药》2 1984.2.29 李大猷，复方降压胶囊的药物配伍分析;《中国农村医学》(5) 1989.5.31 傅善杰，长期服用复方降压片治疗原发性高血压30例分析;《中西医结合杂志》9(7) 1989.7.31 何世银等，威乐降压片治疗高血压病84例疗效观察 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1200269A (en) | 1998-12-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Strauss et al. | Safety and efficacy of diltiazem hydrochloride for the treatment of stable angina pectoris: report of a cooperative clinical trial | |
| RU2002114820A (en) | A method for treating diabetes | |
| CN102008482A (en) | Compound preparation containing valsartan for treating hypertension | |
| CN1279615A (en) | Combination of hypertensin converting enzyme inhibitor with a diuretic for treating microcirculation disorders | |
| Veterans Administration Cooperative Study Group on Antihypertensive Agents et al. | Captopril: evaluation of low doses, twice-daily doses and the addition of diuretic for the treatment of mild to moderate hypertension | |
| Weesner et al. | Cardiac arrhythmias in an adolescent following ingestion of an over-the-counter stimulant. | |
| CN102008710A (en) | Lisinopril-containing compound preparation for treating hypertension | |
| WO2004004664A3 (en) | Methods for treating or preventing ischemic injury | |
| CN1062133C (en) | Medicine for treating hypertensional sickness | |
| JPH02131422A (en) | Medicine for diabetes mellitus | |
| EP0595716A1 (en) | Enhancer for the antianemia effect of erythropoietin | |
| Johns | Cardiac arrest following induction with propanidid | |
| AU710937B2 (en) | Remedies for anxiety neurosis | |
| DEVlKA et al. | A randomized double-blind controlled study of nimodipine in acute cerebral ischemic stroke | |
| MILLS et al. | Treatment of hypertension with orally and parenterally administered purified extracts of veratrum viride: comparison with ganglionic (hexamethonium) and adrenergic blocking agents | |
| CN1965933B (en) | Medicated tea for lowering blood pressure and method for preparing same | |
| Moore et al. | Nonsteroidal Anti-inflammatory Intolerance: An Anaphylactic Reaction to Tolmetin | |
| CN1744896B (en) | Pharmaceutical composition combining tenatoprazole and a histamine h2-receptor antagonist | |
| Kovacs et al. | The effect of an oral evening dose of nizatidine on nocturnal and peptone-stimulated gastric acid and gastrin secretion | |
| CN107737108A (en) | A kind of combination of oral medication for treating Pathogenesis of Post-infarction Ventricular Remodeling | |
| CN109865128A (en) | A Bilutai is treating and preventing the application in diabetes complicated with cerebral infarction drug | |
| 朝居祐貴 et al. | Evaluation of Disopyramide Efficacy for Refractory Syncope in Heart Failure with Preserved Ejection Fraction Using Holter Electrocardiography: A Case Report | |
| CN109568481A (en) | A kind of Chinese prescription preparation for treating coronary heart disease | |
| DE3627613A1 (en) | PHARMACEUTICAL PREPARATION | |
| Olesen | Emergency treatment of excessive hyperkaliemia with ominous ECG-signs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |